Andere talen Immix Biopharma, Inc.

Aandelen

IMMX

US45258H1068

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
2,17 ^USD	0,00%		+1,88%	-68,64%

29/04	Immix Biopharma krijgt label weesgeneesmiddel in Europa voor behandeling van multipel myeloom	MT
18/04	Immix Biopharma, Inc. kondigt aan op schema te liggen voor het doseren van NXC-201-patiënten in de Verenigde Staten	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment	29/04
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in Multiple Myeloma	29/04
Immix Biopharma on Track to Dose First Patients with AL Amyloidosis Therapy by Mid-Year	18/04
Immix Biopharma on Track to Dose NXC-201 Patients in United States	18/04
Immix Biopharma, Inc. Announces on Track to Dose NXC-201 Patients in United States	18/04
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy	16/04
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)	15/04
Immix Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/03
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20/03
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial	20/03
Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial	20/03
Immix Biopharma Announces 'Be Proactive in AL' AL Amyloidosis Awareness Initiative	06/03
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05/03
Immix Biopharma Announces “Be Proactive in AL” AL Amyloidosis Awareness Initiative	05/03
Immix Biopharma 12 Month Review Progress Update	21/02
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08/02
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock	08/02
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07/02
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis	07/02
Immix Biopharma Prices $15 Million Stock Offering	06/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Immix Biopharma, Inc.

Aandelen

IMMX

US45258H1068

Andere talen

Filters